The "Undetermined Significance" of 18F-FDG PET/CT or PET/MRI in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
Giorgio TregliaFrancesco BertagnaDomenico AlbanoPublished in: Medicina (Kaunas, Lithuania) (2021)
Monoclonal gammopathy of undetermined significance (MGUS) is a highly prevalent condition with the possible risk of progression to multiple myeloma (MM) or a lymphoproliferative neoplasm in a small percentage of patients. Fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance imaging (PET/MRI) are imaging methods increasingly used in patients with MM. The aim of this communication is to underline that, taking into account current evidence-based data, compared to MM the role of 18F-FDG PET/CT or PET/MRI in MGUS is still undetermined and more studies should be performed before suggesting 18F-FDG PET/CT or PET/MRI for evaluation of MM progression in patients with MGUS.
Keyphrases
- positron emission tomography
- computed tomography
- magnetic resonance imaging
- contrast enhanced
- pet ct
- multiple myeloma
- pet imaging
- diffusion weighted imaging
- end stage renal disease
- dual energy
- high resolution
- newly diagnosed
- chronic kidney disease
- image quality
- peritoneal dialysis
- big data
- photodynamic therapy
- low grade
- electronic health record
- artificial intelligence